Catadegbrutinib

Overview

BGB-16673 (BGB-16673) is an orally active, selective BTK PROTAC degrader (IC 50 =0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase , causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome , thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma. (Pink: Btk ligand ( HY-175788 ); Blue: Cereblon ligand ( HY-W245311 ); Black: linker).

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Btk | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-160141
• CAS No.: 2736508-60-2
• Molecular Formula: C47H54N12O4
• Molecular Weight: 851.01
• Purity: 99.18%
• Storage: 4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Availability: In-stock

Source

Original product source